Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20
#What Are The Current (2025) And Forecast (2029) Sizes Of The Bronchiolitis Obliterans Syndrome Market?
The market size for bronchiolitis obliterans syndrome has demonstrated robust growth in recent years. It is projected to expand from $1.46 billion in 2024 to $1.59 billion in 2025, reflecting a compound annual growth rate (CAGR) of 9.2%. This historical increase can be attributed to the rising incidence of post-transplant complications, increased awareness among healthcare professionals, expanded utilization of immunosuppressive therapies, an intensified research focus on rare pulmonary disorders, and the wider adoption of advanced diagnostic imaging and lung function tests.
The market size for bronchiolitis obliterans syndrome is projected to experience substantial expansion in the coming years. It is anticipated to reach a valuation of $2.23 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 8.9%. This growth during the forecast period can be attributed to several factors, including an increase in lung transplant procedures globally, a growing pipeline of targeted BOS therapies, rising government and private funding for orphan diseases, an increase in collaborations and licensing agreements, and a growing demand for personalized medicine and biomarkers. Key trends influencing the forecast period encompass advancements in inhaled drug delivery systems, the integration of artificial intelligence in pulmonary diagnostics, technology-driven development of precision medicine, developments in bioinformatics and clinical trial analytics, and improvements in immunomodulatory therapies.
Unlock Your Free Sample Report for Exclusive Market Data:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24488&type=smp
Which Drivers Are Impacting The Bronchiolitis Obliterans Syndrome Market?
The bronchiolitis obliterans syndrome market is anticipated to expand due to the increasing volume of lung transplantations. This procedure involves surgically replacing a diseased or non-functional lung with a healthy donor lung to enhance respiratory function. The rise in these operations can be attributed to advancements in surgical techniques, which have substantially boosted success rates and minimized complications, thereby making the procedure safer and more accessible for patients in need. For individuals with advanced bronchiolitis obliterans syndrome, lung transplantation offers an effective treatment by substituting affected lungs with healthy ones, thus improving respiration and overall lung performance. An illustration of this trend is seen in the data from the Organ Procurement and Transplantation Network, a US-based non-profit scientific and educational organization, which reported in January 2025 that lung transplants showed the largest proportional increase, climbing from 3,026 transplants in 2023 to 3,340 in 2024, representing a 10.4 percent growth. Consequently, the expanding number of lung transplants is a significant factor driving the growth of the bronchiolitis obliterans syndrome market.
What Are The Major Segment Types Covered In The Bronchiolitis Obliterans Syndrome Market?
The bronchiolitis obliterans syndrome market covered in this report is segmented –
1) By Treatment Type: Medication, Oxygen Therapy, Lung Transplant
2) By Diagnosis: Pulmonary Function Tests, Imaging Tests, Lung Biopsy, Other Diagnosis
3) By Disease Type: Acute Bronchiolitis, Chronic Bronchiolitis Obliterans Syndrome
4) By End-User: Hospitals, Specialty Clinics, Diagnostic Centers, Other End-Users
Subsegments:
1) By Medication: Immunosuppressants, Corticosteroids, Antibiotics, Bronchodilators, Anti-Inflammatory Agents
2) By Oxygen Therapy: Continuous Oxygen Therapy, Intermittent Oxygen Therapy, Portable Oxygen Therapy, Hyperbaric Oxygen Therapy
3) By Lung Transplant: Single Lung Transplant, Double Lung Transplant, Living Donor Lung Transplant, Retransplantation
What Are The Major Trends Driving The Growth Of The Bronchiolitis Obliterans Syndrome Market?
Leading entities within the bronchiolitis obliterans syndrome market are concentrating on creating sophisticated remedies, including at-home nebulized therapy. This approach aims to improve medication compliance and impede the advancement of the illness via precise, ongoing therapeutic interventions. This at-home nebulized therapy method utilizes a nebulizer to convert liquid drugs into a fine, inhalable mist, facilitating their direct dispersion into the lungs. Such a user-friendly, self-managed treatment option allows for the efficient handling of respiratory ailments within a home setting. An illustrative example occurred in March 2023, when Renovion, Inc., a US-based clinical-stage pharmaceutical company, introduced ARINA-1. This product was granted Food and Drug Administration (FDA) Fast Track Designation because its objective is to halt the progression of bronchiolitis obliterans syndrome (BOS) in individuals who have undergone bilateral lung transplants. This significant regulatory achievement highlights ARINA-1’s capacity to address a vital, underserved medical requirement in the field of transplant medicine. The Fast Track status facilitates more frequent interactions with the FDA and gives ARINA-1 priority for expedited development and evaluation, which demonstrates Renovion’s dedication to improving respiratory health through inventive, patient-centric therapeutic solutions.
Who Are The Key Multinational Companies Dominating The Bronchiolitis Obliterans Syndrome Market?
Major companies operating in the bronchiolitis obliterans syndrome market are Pfizer Inc., Boehringer Ingelheim, University of California Health, Texas Children’s Hospital, Incyte Corporation, Apollo Hospitals, Mallinckrodt Pharmaceuticals plc, Zambon Company S.p.A., Fortis Healthcare, St. Louis Children’s Hospital, Mayo Foundation for Medical Education and Research, Medicover Hospitals, Renovion Inc., Mereo BioPharma Group PLC, OrphAI Therapeutics, Koutif Therapeutics, ArkBio, Altavant Sciences, Breath Therapeutics, University of Alberta Hospital
Download The Full Report For Exclusive Market Findings:
Which Region Is Expected To Witness The Fastest Growth In The Bronchiolitis Obliterans Syndrome Market?
North America was the largest region in the bronchiolitis obliterans syndrome market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the bronchiolitis obliterans syndrome market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Version Of The Bronchiolitis Obliterans Syndrome Market Report:
https://www.thebusinessresearchcompany.com/customise?id=24488&type=smp
Browse Through More Reports Similar to the Global Bronchiolitis Obliterans Syndrome Market 2025, By The Business Research Company
Bronchitis Treatment Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/bronchitis-treatment-global-market-report
Reversible Airway Diseases Treatment Global Market Report 2025
Tracheitis Treatment Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/tracheitis-treatment-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model